The Otoscan launch is off to a solid start, and CEO Jonathan Kennedy sees a lot of potential for the technology. Adjusted EPS factors out one-time issues such as restructuring costs, which is a better way to look at the overall health of Natus' underlying business.Natus continues to make headway in reducing costs, including eliminating one of its three Midwest facilities to help make its supply chain more efficient.The company also introduced four new neurodiagnostic products during the quarter. The new Otoscan machine that scans the inside of the ear to create a digital image for fitting hearing aids launched during the quarter with more than 50 units installed in the field. grew, but there were some issues overseas, especially in Iran due to sanctions, and in Turkey, where the currency has been devalued, making foreign products too expensive. The Otometrics hearing-aid fitting business, which makes up another quarter of sales, was basically flat year over year with the unit registering revenue growth of 0.1%.Some of the decrease was from previously announced decisions to stop selling some products, and the devaluation of the Argentine peso also hurt revenue growth for the division. The newborn-care business, which makes up about a quarter of the total revenue, continues to struggle, with sales down 7.3%.Most of the growth came from acquired business over the last year, but organic growth was up 2.1%, and changes in foreign exchange rates contributed another 0.5%. The neurology products, which make up about half the business, helped boost the overall revenue with a 17.6% year-over-year increase.Natus is a leading provider of medical device solutions focused on the diagnosis and treatment of central nervous and sensory system disorders for patients of all ages.What happened with Natus Medical this quarter? The common stock will continue to be listed on NASDAQ and the CUSIP will remain unchanged as 639050103. No action is needed from Natus’ current shareholders relative to the ticker symbol change. The new ticker symbol better reflects our identity as a global provider of innovative healthcare solutions focused on the diagnosis and treatment of central nervous and sensory system disorders for patients of all ages.” “We have diversified our products, solutions, and core capabilities well beyond the neonatal care market since our IPO in 2001. “We are excited to begin trading under the new symbol, NTUS,” said Jonathan Kennedy, President and Chief Executive Officer of Natus. Trading under the new ticker symbol will begin at the open of the market on Friday, July 26, 2019. PLEASANTON, Calif., J(GLOBE NEWSWIRE) - Natus Medical Incorporated (NASDAQ: NTUS) (the “Company” or “Natus”), a leading provider of medical device solutions focused on the diagnosis and treatment of central nervous and sensory system disorders for patients of all ages, today announced that the Company's ticker symbol on the Nasdaq Global Select Market (NASDAQ) will change to “NTUS” from “BABY”.
0 Comments
Leave a Reply. |